Stay updated on Cabotegravir vs TDF/FTC in Women Clinical Trial
Sign up to get notified when there's something new on the Cabotegravir vs TDF/FTC in Women Clinical Trial page.

Latest updates to the Cabotegravir vs TDF/FTC in Women Clinical Trial page
- Check6 days agoChange DetectedAdded a consolidated Locations section listing study sites (South-East District, Nyanza, Central Region, Gauteng, KwaZulu-Natal, Western Cape, Mashonaland East Province) and updated the revision tag to v3.3.3; removed the previous 'X Locations' subheadings (e.g., 'South-East District Locations', 'Nyanza Locations').SummaryDifference0.7%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedPublication notes updated to indicate PubMed-sourced publications are automatically filled and the page revision was updated to v3.3.2; the older version note referencing v3.2.0 was removed.SummaryDifference0.1%

- Check42 days agoChange DetectedThe government funding notice banner at the top of the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check56 days agoChange DetectedNo core content changes detected (no pricing, stock, or time-slot updates); the Study Details page remains unchanged in purpose and content, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check77 days agoChange DetectedPage content updated with new future dates and a new Mbabane, Eswatini reference; older Eswatini location mentions and prior Last Update line removed.SummaryDifference0.7%

- Check85 days agoChange DetectedCore content updated with a new operating-status notice and a version bump to v3.2.0; previous v3.1.0 reference removed.SummaryDifference2%

Stay in the know with updates to Cabotegravir vs TDF/FTC in Women Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabotegravir vs TDF/FTC in Women Clinical Trial page.